论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
Authors Yang K, Jiang B, Lu Y, Shu Q, Zhai P, Zhi Q, Li Q
Received 28 August 2018
Accepted for publication 1 February 2019
Published 1 May 2019 Volume 2019:11 Pages 3779—3790
DOI https://doi.org/10.2147/CMAR.S185438
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Andrew Yee
Peer reviewer comments 2
Editor who approved publication: Dr Beicheng Sun
Purpose: Our
previous study proved that FOXM1 regulates colorectal cancer (CRC) cell
metastasis through epithelial–mesenchymal transition program. The aim of this
study is to further explore the underlying mechanism of FOXM1 in CRC.
Materials and methods: In this
study, we detected the mRNA and protein expressions of FOXM1 and β-catenin in
CRC tissues and their corresponding normal-appearing tissues (NATs) by
quantitative reverse transcription-PCR and western blot analysis, respectively.
Then the potential link between FOXM1 and β-catenin in CRC tissues was
analyzed. Furthermore, we systematically analyzed the biological functions of
FOXM1 in CRC cells after reconstitution of FOXM1 expression in vitro. Moreover,
the mechanism of FOXM1-promoted CRC progression by improving β-catenin nuclear
translocation was also discussed.
Results: Our data
demonstrated that FOXM1 and β-catenin were upregulated in CRC tissues compared
with the corresponding NATs (P <0.05). Clinicopathologic analysis revealed that
increased FOXM1 (or β-catenin) expression positively correlated with some
clinicopathologic features, such as tumor size, TNM stage, lymphatic
metastasis, and distant metastasis (P <0.05). Meanwhile, the possible relationships
between FOXM1 and β-catenin in CRC samples were evaluated using SPSS software,
and a significant positive correlation was found (P <0.05). In
vitro data demonstrate that elevated FOXM1 expression exerted oncogenic effects
on CRC via activation of β-catenin signaling pathway. The inhibition of
β-catenin by siRNAs significantly attenuates FOXM1-induced malignant
activities.
Conclusion: The data
suggested that FOXM1/β-catenin is critical for malignancy of CRC, which may
constitute a potential therapeutic strategy for CRC.
Keywords: FOXM1,
β-catenin, colorectal cancer, signaling pathway